Electroactive pore

• US 6,490,483 B2
• Filed: 06/11/2001
• Issued: 12/03/2002
• Est. Priority Date: 02/18/1999
• Status: Expired due to Term

• Current Assignee: Valeritas, Inc. (Zealand Pharma A/S)
• Original Assignee: Biovail Laboratories Incorporated (Bausch Health Cos., Inc.)
• Inventors: Willis, John
• Primary Examiner(s): KENNEDY, SHARON E
• Application Number:
  US09/878,573
• Publication Number:
  US 20010029348A1
• Time in Patent Office: 540 Days
• Field of Search: 604/20, 604/21, 604/500, 604/501
• US Class Current: 604/20
• CPC Class Codes: A61B 2562/028 Microscale sensors, e.g. electromechanical sensors [MEMS]
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/14546 for measuring analytes not otherwise provided for, e.g. ions, cytochromes
• CPC Class Codes: A61B 5/4839 combined with drug delivery
• CPC Class Codes: A61N 1/30 Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis

Abstract

Electroactive pores, devices including one or more electroactive pores are described, and methods of delivering therapeutic agents using one or more electroactive pores are described.

Claims

1. A method of administering a therapeutic agent, comprising:

passing the therapeutic agent through a device, comprising;

a layer of material having a pore passing therethrough;

an electroactive polymer disposed so that when the electroactive polymer has a first state of charge a therapeutic agent has a first ability to pass through the pore, and when the electroactive pore has a second state of charge different from the first state of charge the therapeutic agent has a second ability to pass through the pore different than the first ability to pass through the pore; and

a BETA associated with the electroactive polymer,

wherein the electroactive polymer is at least partially disposed within the pore.

2. The method of claim 1, further comprising charging the electroactive polymer.

3. The method of claim 2, wherein charging the electroactive polymer includes biasing the electroactive polymer.

4. The method of claim 3, wherein the bias is selected from the group consisting of a fixed bias, a variable bias and a cyclical bias.

5. A method of administering a therapeutic agent, comprising:

passing the therapeutic agent through a device, comprising;

a layer of a material having a pore passing therethrough;

an electroactive polymer disposed so that when the electroactive polymer has a first state of charge a therapeutic agent has a first ability to pass through the pore, and when the electroactive pore has a second state of charge different from the first state of charge the therapeutic agent has a second ability to pass through the pore different than the first ability to pass through the pore; and

a BETA associated with the electroactive polymer,

wherein the BETA comprises glucose oxidase.

6. The method of claim 5, further comprising charging the electroactive polymer.

7. The method of claim 6, wherein charging the electroactive polymer includes biasing the electroactive polymer.

8. The method of claim 7, wherein the bias is selected from the group consisting of a fixed bias, a variable bias and a cyclical bias.

9. A method of administering a therapeutic agent, comprising:

passing the therapeutic agent through a device, comprising;

a layer of material having a pore passing therethrough;

an electroactive polymer disposed so that when the electroactive polymer has a first state of charge a therapeutic agent has a first ability to pass through the pore, and when the electroactive pore has a second state of charge different from the first state of charge the therapeutic agent has a second ability to pass through the pore different than the first ability to pass through the pore;

a BETA associated with the electroactive polymer; and

a mediator that mediates charge transfer between the electroactive pore and the member.

10. The method of claim 9, further comprising charging the electroactive polymer.

11. The method of claim 10, wherein charging the electroactive polymer includes biasing the electroactive polymer.

12. The method of claim 11, wherein the bias is selected from the group consisting of a fixed bias, a variable bias and a cyclical bias.

13. A method of administering a therapeutic agent, comprising:

passing the therapeutic agent through a device, comprising;

a layer of a material having a pore passing therethrough;

an electroactive polymer disposed so that when the electroactive polymer has a first state of charge a therapeutic agent has a first ability to pass through the pore, and when the electroacive pore has a second state of charge different from the first state of charge the therapeutic agent has a second ability to pass through the pore different than the first ability to pass through the pore;

a BETA associated with the electroactive polymer; and

a mediator that mediates charge transfer between the electroactive pore and an analyte.

14. The method of claim 13, further comprising charging the electroactive polymer.

15. The method of claim 14, wherein charging the electroactive polymer inlcudes biasing the electroactive polymer.

16. The method of claim 15, wherein the bias is selected from the group consisting of a fixed bias, a variable bias and a cyclical bias.

17. A method of administering a therapeutic agent, comprising:

passing the therapeutic agent through a device, comprising;

a layer of a material having a pore passing therethrough;

an electroactive polymer disposed so that when the electroactive polymer has a first state of charge a therapeutic agent has a first ability to pass through the pore, and when the electroactive pore has a second state of charge different from the first state of charge the therapeutic agent has a second ability to pass through the pore different than the first ability to pass through the pore; and

a BETA associated with the electroactive polymer,

wherein the electroactive polymer comprises a polymer comprising a component selected from the group consisting of thiophen, derivatives of thiophen, phenylene, derivatives of phenylene, diamine, derivatives of diamine, pyrrole, derivatives of pyrrole, aniline, derivatives of aniline, and combinations thereof, and

the BETA comprises glucose oxidase.

18. The method of claim 17, further comprising charging the electroactive polymer.

19. The method of claim 18, wherein charging the electroactive polymer includes biasing the electroactive polymer.

20. The method of claim 19, wherein the bias is selected from the group consisting of a fixed bias, a variable bias and a cyclical bias.